Form 4: AC Immune CEO Andrea Pfeifer Increases Stake in ACIU
Statement of Changes in Beneficial Ownership
CEO Andrea Pfeifer purchased 10,000 shares of AC Immune SA at a weighted average price of $3.1425 per share.
Summary
- CEO Andrea Pfeifer acquired 10,000 common shares of AC Immune SA on April 15, 2026.
- The purchase was executed at a weighted average price of $3.1425, with individual transaction prices ranging from $3.05 to $3.19.
- Following this transaction, the CEO directly owns 3,830,288 shares, which includes 1,921,005 shares underlying restricted share units.
- The reporting person also maintains an indirect interest in 14,000 shares held by her spouse.
- The transaction was conducted pursuant to a Rule 10b5-1 trading plan.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive signal, as the CEO's decision to increase her personal investment in the company suggests confidence in the firm's future prospects.
Positives
- Insider confidence is demonstrated by the CEO increasing her equity stake in the company.
- The purchase was made at market prices, signaling alignment with shareholder interests.
Negatives
- None identified in this filing.
Risks
- The transaction was executed under a Rule 10b5-1 plan, which is a pre-arranged trading schedule, limiting the ability to react to immediate market changes.
Future Outlook
No forward-looking guidance provided in this filing.
Industry Context
StockSavvy.ai notes that insider buying in the biotechnology sector is often viewed as a positive signal of management's belief in the company's clinical pipeline and long-term valuation, particularly when occurring at current market levels.
Comparison to Industry Standards
- Insider purchases by CEOs are generally considered a standard positive indicator of corporate health and confidence in the sector.
- The use of Rule 10b5-1 plans is standard practice for executives to avoid potential conflicts of interest regarding material non-public information.
Stakeholder Impact
- Shareholders may interpret this purchase as a vote of confidence from leadership.
Key Dates
| Date | Description |
|---|---|
| 04/15/2026 | Date of the reported share purchase transaction. |
| 04/16/2026 | Date the Form 4 was signed and filed. |
Keywords
AC Immune, ACIU, Insider Trading, CEO, Biotech, Equity Purchase
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.